摘要
目的:观察小剂量美托洛尔对重症心衰患者心功能指标及不良反应的影响。方法:选取本院2019年1月-2020年1月收治的重症心衰患者84例。随机分为研究组与对照组,各42例。对照组给予常规治疗,研究组在对照组基础上联合小剂量美托洛尔治疗。观察两组临床疗效、心功能指标[左心室射血分数(LVEF)、N末端B型利钠肽原(NT-proBNP)]和不良反应发生情况。结果:研究组治疗总有效率(88.10%)显著高于对照组(66.67%),差异有统计学意义(P<0.05)。治疗前,两组LVEF、NT-proBNP水平比较差异无统计学意义(P>0.05);治疗后,两组LVEF水平较治疗前显著上升,且研究组显著高于对照组(P<0.05);治疗后两组NT-proBNP水平较治疗前显著降低,且研究组显著低于对照组(P<0.05)。研究组不良反应总发生率(7.14%)与对照组(11.90%)比较差异无统计学意义(P>0.05)。结论:小剂量美托洛尔治疗重症心衰患者的效果显著,可显著改善患者心功能指标LVEF和NT-proBNP水平,且不良反应较少,可在临床广泛应用。
Objective:To observe the influence of small-dose Metoprolol on cardiac function indicators and adverse reactions in patients with severe heart failure.Method:A total of 84 patients with severe heart failure admitted to our hospital from January 2019 to January 2020 were selected.They were randomly divided into the study group and the control group,42 cases in each group.The control group was given conventional treatment,and the study group was combined with small-dose Metoprolol treatment on the basis of the control group.The clinical efficacy,cardiac function indicators[left ventricular ejection fraction(LVEF)and N-terminal pro-BNP(NT-proBNP)]and adverse reactions after treatment in the two groups were observed.Result:After treatment,the total effective rate of the study group(88.10%)was significantly higher than that of the control group(66.67%),the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of LVEF and NT-proBNP of the two groups(P>0.05);after treatment,the levels of LVEF of the two groups were significantly higher than those before treatment,and the study group was significantly higher than the control group(P<0.05);after treatment,the level of NT-proBNP of the two groups was lower than that before treatment,and the study group was significantly lower than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions in the study group(7.14%)and 11.90%of the control group(P>0.05).Conclusion:Small-dose Metoprolol is effective in treating patients with severe heart failure.It can significantly improve the levels of cardiac function indicators LVEF and NT-proBNP,and has fewer adverse reactions.It can be widely used in clinical practice.
作者
王道正
WANG Daozheng(Laixi People’s Hospital,Laixi 266600,China)
出处
《中外医学研究》
2021年第11期78-80,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
小剂量美托洛尔
重症心衰
心功能指标
不良反应
Small-dose Metoprolol
Severe heart failure
Cardiac function indicators
Adverse reactions
